Source: The Pharmacogenomics Journal. Unidades: FORP, FMRP
Subjects: POLIMORFISMO, METALOPROTEINASES, SÍNDROME DE IMUNODEFICIÊNCIA ADQUIRIDA (TERAPIA), FARMACOGENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DEMACQ, Caroline et al. A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients. The Pharmacogenomics Journal, v. 9, n. 4, p. 265-273, 2009Tradução . . Disponível em: https://doi.org/10.1038/tpj.2009.13. Acesso em: 01 nov. 2024.APA
Demacq, C., Vasconcellos, V. B., Marcaccini, A. M., Gerlach, R. F., Machado, A. A., & Santos, J. E. T. dos. (2009). A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients. The Pharmacogenomics Journal, 9( 4), 265-273. doi:10.1038/tpj.2009.13NLM
Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Machado AA, Santos JET dos. A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients [Internet]. The Pharmacogenomics Journal. 2009 ; 9( 4): 265-273.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1038/tpj.2009.13Vancouver
Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Machado AA, Santos JET dos. A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients [Internet]. The Pharmacogenomics Journal. 2009 ; 9( 4): 265-273.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1038/tpj.2009.13
